Abstract:Regulated cell death (RCD) has always been considered a tolerogenic event. Immunogenic cell death (ICD) occurs as a consequence of tumour cell death accompanied by the release of damage-associated molecular patterns (DAMPs), triggering an immune response. ICD plays a major role in stimulating the function of the immune system in cancer during chemotherapy and radiotherapy. ICD can therefore represent one of the routes to boost anticancer immune responses. According to the recommendations of the Nomenclature Committee on Cell Death (2018), apoptosis (type I cell death) and necrosis (type II cell death) represent are not the only types of RCD, which also includes necroptosis, pyroptosis, ferroptosis and others. Specific downstream signalling molecules and death-inducing stimuli can regulate distinct forms of ICD, which develop and promote the immune cell response. Dying cells deliver different potential immunogenic signals, such as DAMPs, which are able to stimulate the immune system. The acute exposure of DAMPs can prime antitumour immunity by inducing activation of antigen-presenting cells (APC), such as dendritic cells (DC), leading to the downstream response by cytotoxic T cells and natural killer cells (NK). As ICD represents an important target to direct and develop new pharmacological interventions, the identification of bioactive natural products, which are endowed with low side effects, higher tolerability and preferentially inducing immunogenic programmed cell death, represents a priority in biomedical research. The ability of ICD to drive the immune response depends on two major factors, neither of which is intrinsic to cell death: 'Antigenicity and adjuvanticity'. Indeed, the use of natural ICD-triggering molecules, alone or in combination with different (immuno)therapies, can result in higher efficacy and tolerability. Here, we focused on natural (marine) compounds, particularly on marine microalgae derived molecules such as exopolysaccharides, sulphated polysaccharides, glycopeptides, glycolipids, phospholipids, that are endowed with ICD-inducing properties and sulfavants. Here, we discuss novel and repurposed small-molecule ICD triggers, as well as their ability to target important molecular pathways including the IL-6, TNF-α and interferons (IFNs), leading to immune stimulation, which could be used alone or in combinatorial immunotherapeutic strategies in cancer prevention and therapies.

Revealing the mechanism of natural product-induced immunogenic cell death: opening a new chapter in tumor immunotherapy

Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment

Targeting CD8 + T cells with natural products for tumor therapy: Revealing insights into the mechanisms

Natural compound inducers of immunogenic cell death

Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers

Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions

Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds

Natural Products and Their Derivatives: Promising Modulators of Tumor Immunotherapy

Towards Understanding the Molecular Mechanisms of Immunogenic Cell Death

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy.

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Nanomaterials: leading immunogenic cell death-based cancer therapies

Biomaterials That Induce Immunogenic Cell Death

Immunogenic cell death and its emerging inducers:the next generation immunotherapy

Mechanisms of immunogenic cell death and immune checkpoint blockade therapy

Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy

Immunogenic cell death inducers for enhanced cancer immunotherapy

Ferroptosis, Necroptosis, and Pyroptosis in Anticancer Immunity

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review